Eyegate expects to price IPO of 833,333 shares at $6.00 per share

Aegis and Chardan to assist in selling company’s common stock

By Devika Patel

Knoxville, Tenn., Dec. 2 – Eyegate Pharmaceuticals, Inc. will sell 833,333 common shares in its initial public offering with a 45-day greenshoe of 125,000 additional shares, according to a Form S-1/A filed Tuesday with the Securities and Exchange Commission.

The deal was announced July 30, and the company reported on Dec. 2 that it planned to sell 1,428,572 common shares with a 45-day greenshoe of 214,286 shares at a price expected to fall between $6.00 and $8.00 per share. The deal originally was expected to sell shares between $12.00 and $14.00 per share.

The shares will be sold at an expected price of $6.00 per share.

Aegis Capital Corp. and Chardan Capital Markets, LLC are the bookrunning managers.

Proceeds will be used for clinical trials, safety trials, proof-of-concept trials, preclinical studies, working capital and other general corporate purposes.

The pharmaceutical company is based in Waltham, Mass. The company intends to list its common stock on the OTCBB exchange under the symbol “EYEG.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.